$0.86
7.70% today
Nasdaq, Apr 03, 06:19 pm CET
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Inozyme Pharma Inc Stock price

$0.93
-0.16 15.01% 1M
-4.10 81.58% 6M
-1.84 66.56% YTD
-6.00 86.63% 1Y
-3.37 78.46% 3Y
-16.61 94.72% 5Y
-16.61 94.72% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.06 6.48%
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Key metrics

Market capitalization $59.51m
Enterprise Value $-7.02m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.08
P/B ratio (TTM) P/B ratio 1.03
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-104.03m
Free Cash Flow (TTM) Free Cash Flow $-91.97m
Cash position $113.40m
EPS (TTM) EPS $-1.62
P/E forward negative
Short interest 6.71%
Show more

Is Inozyme Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Inozyme Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

Buy
100%

Financial data from Inozyme Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.85 0.85
34% 34%
-
-0.85 -0.85
34% 34%
-
- Selling and Administrative Expenses 20 20
4% 4%
-
- Research and Development Expense 83 83
53% 53%
-
-103 -103
39% 39%
-
- Depreciation and Amortization 0.85 0.85
34% 34%
-
EBIT (Operating Income) EBIT -104 -104
38% 38%
-
Net Profit -102 -102
43% 43%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inozyme Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inozyme Pharma Inc Stock News

Neutral
GlobeNewsWire
3 days ago
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual H...
Neutral
GlobeNewsWire
24 days ago
- Cash, cash equivalents and short-term investments as of December 31, 2024, and anticipated cost savings from prioritizing ENPP1 Deficiency program, including an approximately 25% workforce reduction, expected to support operations into the first quarter of 2026 - - Enrollment complete in ENERGY 3 pivotal trial in pediatric patients with ENPP1 Deficiency; topline data expected in first quarter...
Neutral
GlobeNewsWire
about one month ago
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the TD Cowen 45th Annual Health Care Conference on Monday...
More Inozyme Pharma Inc News

Company Profile

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Head office United States
CEO Doug Treco
Employees 67
Founded 2015
Website www.inozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today